Literature DB >> 8319752

Brain temperature and the neuroprotective action of enadoline and dizocilpine in the gerbil model of global ischaemia.

N J Hayward1, A T McKnight, G N Woodruff.   

Abstract

Mongolian gerbils were subjected to transient forebrain ischaemia by occluding both common carotid arteries for 7 min. Subcutaneous administration of either the kappa-opioid receptor agonist enadoline (CI-977; 1 mg kg-1), or the non-competitive NMDA receptor antagonist dizocilpine (MK-801; 3 mg kg-1), at induction of ischaemia prevented neurodegeneration of CA1-CA2 pyramidal neurones in the dorsal hippocampus. It was shown by continuously monitoring intrahippocampal temperature that brain temperature drops by approximately 4 degrees C during ischaemia, when rectal temperature is maintained normothermic. Enadoline at no time point tested affected brain temperature, whereas dizocilpine statistically lowered brain temperature following ischaemia. These findings suggest that enadoline affords neuroprotection in the absence of any hypothermic episode, whilst in the case of dizocilpine, the small transient hypothermia observed following ischaemia may act synergistically or additively with the drug to yield neuroprotection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8319752     DOI: 10.1016/0014-2999(93)90595-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  Postischemic hypothermia. A critical appraisal with implications for clinical treatment.

Authors:  F Colbourne; G Sutherland; D Corbett
Journal:  Mol Neurobiol       Date:  1997-06       Impact factor: 5.590

2.  Kappa Opioid Receptor Agonist and Brain Ischemia.

Authors:  Chen Chunhua; Xi Chunhua; Sugita Megumi; Liu Renyu
Journal:  Transl Perioper Pain Med       Date:  2014

3.  Role of miR-326 in neonatal hypoxic-ischemic brain damage pathogenesis through targeting of the δ-opioid receptor.

Authors:  Xuan Wang; Han Zhou; Rui Cheng; Xiaoguang Zhou; Xuewen Hou; Jun Chen; Jie Qiu
Journal:  Mol Brain       Date:  2020-03-30       Impact factor: 4.041

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.